Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
CAMBRIDGE, Mass. , Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that updated data from the Phase 2 PIONEER trial of avapri...
CAMBRIDGE, Mass. , Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in fireside chats at the follow...
Penny stocks might seem like a good investment because you can purchase many shares for a relatively small amount of money. But most of them represent businesses with questionable prospects at best, and owning thousands of shares of a worthless venture means your hard-earned money could vaporize...
Image source: The Motley Fool. Blueprint Medicines (NASDAQ: BPMC) Q4 2019 Earnings Call Feb 13, 2020 , 8:30 a.m. ET Operator Continue reading
Blueprint Medicines Corporation (BPMC) Q4 2019 Results Earnings Conference Call February 13, 2020, 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, Investor Relations Jeff Albers - Chief Executive Officer Dr. Andy Boral - Chief Medical Officer Christy Rossi - Ch...
Blueprint Medicines (NASDAQ: BPMC ): Q4 GAAP EPS of -$1.35 beats by $0.41 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the fourth quart...
Blueprint's (Most Recent) Raise Closed: TBD (proposed pricing on 1/22/20) Pricing: $69.00/share Amount: ~$325 million Over-allotment: TBD Blueprint Medicines ( BPMC ) recently announced a dilutive raise, sending share prices below key moving averages: Blueprint's la...
CAMBRIDGE, Mass. , Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webcast at 8:30 a.m...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...